Exenatide, a GLP-1 receptor agonist licensed to treat type 2 diabetes, and recently shown to be associated with reduced severity of PD
pubmed.ncbi.nlm.nih.gov/32247373/
pubmed.ncbi.nlm.nih.gov/33409802/
1 completed research findings
www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31585-4/fulltext
Exenatide had positive effects on practically defined off-medication motor scores in Parkinson’s disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson’s disease, and effects on everyday symptoms should be examined in longer-term trials.
Supplement alternative – Glutamine >>
A Report of 10 cases of Parkinson’s Disease cured by Xifengzhizhan pills and Xifengzhizhan capsules, Wang Weifan
A Report of 10 cases of Parkinson’s Disease cured by Xifengzhizhan pills and Xifengzhizhan capsules, Wang Weifan
treatment based on traditional Chinese herbal medicine